(RPRX, GBLHF, CBK, CNK, QTM) Noticeable Stock by Stock-PR.com

Stock-PR Reporting

FREE Daily Stock Alerts From Stock-PR.com

Repros Therapeutics Inc.(R) (Nasdaq:RPRX) provided top line results for the end of dosing analysis on its Phase 2 clinical study of Androxal(R) in hypogonadal men with type 2 diabetes. Many men with secondary hypogonadism also have type 2 diabetes. A total of 108 men completed the three month dosing period and were the basis for this analysis. The study was conducted at 19 clinical sites in the US. A total of 119 men were enrolled in the study and satisfied the requirement of one visit in which efficacy measures could be assessed and are included in the intent to treat population. Outcomes for the “completer” and intent to treat populations were similar.

At baseline, mean morning testosterone levels for the three groups were; placebo (238 ng/dl), 12.5 mg Androxal (244 ng/dl) and 25 mg Androxal (246 ng/dl). There was no statistical difference between the groups in testosterone at baseline. At the end of the 3 month dosing period mean morning testosterone levels were placebo (231 ng/dl), 12.5 mg Androxal (445 ng/dl) and 25 mg Androxal (455 ng/dl). A comparison of either the 12.5 mg or 25 mg dose of Androxal to placebo showed them to be highly statistically different (p< 0.0001). There was no statistical difference between the two active arms. In previous Repros studies in men with low testosterone due to a variety of reasons, there was a dose dependent increase in testosterone levels.

Including all men that completed the 3 month dosing, there was a trend towards improved glycemic control in the men on the 25 mg dose. Men on the 25 mg dose saw a reduction of HbA1c (glycosylated hemoglobin) of 0.159% and a reduction of HOMA-IR (a measure of insulin resistance calculated by measuring fasting plasma glucose and insulin) of 2.89 units. Additionally, the change in HOMA-IR approached statistical significance (p=0.09) for men on the 25 mg dose. In the Intent-to-Treat population of men receiving 25 mg Androxal and who were younger than 65 years of age, the mean change in HbA1c was -0.385% which when compared to placebo men of the same age group (+0.145%) yielded a near statistically significant outcome, p=0.058.

To date, studies of testosterone replacement therapy in diabetic men conducted by others have shown no statistical difference comparing testosterone treatment to placebo when assessing impact on HbA1c levels after treatment. Trials completed by Repros have shown that unlike testosterone replacement therapy, Androxal stimulates normal production of the male hormone by the testes.

The drug was generally well tolerated at both doses compared to placebo. There were no drug related serious adverse events that led to discontinuation. The Company plans to hold a joint meeting with the Endocrine and Urologic Divisions of the FDA to discuss these and other findings.

Repros Therapeutics focuses on the development of oral small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

More about RPRX at www.reprosrx.com.

*******************************

Global Hunter Corp. (GBLHF)

Copper is an excellent electrical conductor. Most of its uses are based on this property or the fact that it is also a good thermal conductor. However, many of its applications also rely on one or more of its other properties. For example, it wouldn’t make very good water and gas pipes if it were highly reactive.

Global Hunter Corp. (GBLHF.PK) is pleased to announce initial assay results from its previously announced surface sampling program. The results are encouraging with new gold showings as well as very positive copper oxide assays over wide-spread areas.

Highlights of the entire program

9 mineralized shear and/or alteration zones sampled total of 13.5 kilometers of strike length along know copper bearing shear and alteration zones tested with 205 rock chip samples

Good grades of soluble copper (oxide) over a significantly large area have been identified, however they represent only about 50% of the total copper grade indicating a mixed oxide-sulphide zone. Numerous iron oxide structures have also been mapped but no iron assays have been received to date.

The Company is planning to re-assay samples for iron to determine if iron is present in significant quantities to represent another target.

Global Hunter’s focus is on strategic and base metals, with an advanced stage copper oxide project in Chile and a highly prospective molybdenum property in British Columbia, Canada. GBLHF exploration and development teams are on the ground rapidly advancing the La Corona de Cobre property near La Serena, Chile and the Rabbit South property in British Columbia, Canada. Either one of these projects could carry the company forward on a stand-alone basis, but together they bring the company additional stability, strength and value.

http://www.globalhunter.ca/homeabout.html

************************

Christopher & Banks Corporation (NYSE:CBK) announced that it plans to report its fiscal 2012 third quarter financial results on Thursday, December 22, 2011, after the market close. The Company also plans to hold a conference call to discuss its financial results at 4:30 p.m. ET on Thursday, December 22, 2011.

Christopher & Banks Corporation is a Minneapolis-based specialty retailer of women’s clothing.

************************

Cinemark Holdings, Inc. (NYSE:CNK), one of the leading motion picture exhibitors in the world, announced that Mission: Impossible - Ghost Protocol will be shown in Cinemark’s XD auditoriums and IMAX auditoriums starting Thursday, December 15, six days in advance of the film’s December 21 wide release. Cinemark has XD & IMAX auditoriums located in over 60 markets across the US.

Headquartered in Plano, TX, Cinemark Holdings, Inc. is a leader in the motion picture exhibition industry with 448 theatres and 5,096 screens in the U.S. and Latin America as of September 30, 2011.

************************

Quantum Corp. (NYSE:QTM), a proven global expert in data protection and big data management, announced that the company’s vmPRO 4000 integrated solution for protecting data on virtual servers was named “Storage Virtualization Product of the Year” at the 2011 Storage, Virtualization and Cloud Computing (SVC) Awards. The award recognizes Quantum’s commitment to building on its data protection expertise by combining innovative technologies and adding unique value to meet customers’ evolving storage needs.

Quantum Corp. (NYSE:QTM) is a proven global expert in data protection and big data management. From small businesses to multinational enterprises, more than 50,000 customers trust Quantum to solve their data protection, retention and management challenges.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Sign Up For Free Stock Alerts At http://stock-pr.com/signup

<